2026-06-27T10:43:35Zhttps://docta.ucm.es/rest/oai/request
oai:docta.ucm.es:20.500.14352/48732024-09-06T14:59:20Zcom_20.500.14352_14col_20.500.14352_15
Docta Complutense author Delgado Valero, Beatriz author Cachofeiro Ramos, María Victoria author Martínez Martínez, Ernesto 2023-06-16T14:22:44Z 2023-06-16T14:22:44Z 2021-07-19 Delgado Valero, B., Cachofeiro Ramos, M. V., Martínez Martínez, E. et al. «Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved». Cells, vol. 10, n.o 7, julio de 2021, p. 1824. DOI.org (Crossref), https://doi.org/10.3390/cells10071824. 2073-4409 10.3390/cells10071824 https://hdl.handle.net/20.500.14352/4873 https://doi.org/10.3390/cells10071824 https://www.mdpi.com/2073-4409/10/7/1824/htm Cardiorenal syndrome is a term that defines the complex bidirectional nature of the interaction between cardiac and renal disease. It is well established that patients with kidney disease have higher incidence of cardiovascular comorbidities and that renal dysfunction is a significant threat to the prognosis of patients with cardiac disease. Fibrosis is a common characteristic of organ injury progression that has been proposed not only as a marker but also as an important driver of the pathophysiology of cardiorenal syndromes. Due to the relevance of fibrosis, its study might give insight into the mechanisms and targets that could potentially be modulated to prevent fibrosis development. The aim of this review was to summarize some of the pathophysiological pathways involved in the fibrotic damage seen in cardiorenal syndromes, such as inflammation, oxidative stress and endoplasmic reticulum stress, which are known to be triggers and mediators of fibrosis. eng Atribución 3.0 España Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved journal article URL https://docta.ucm.es/bitstreams/a739e649-5456-4c90-8ac9-51dbab0bfc35/download File MD5 55d6c300f3285eefa0ca493f5f05318f 1947323 application/pdf cells-10-01824-v2.pdf